Of all promising candidate drugs, >94% fail during clinical trials, with each failure costing $0.8-1.6 billion. Epiloid screens these failing drugs before they reach the clinical stage by combining assays on human brain organoids and advanced machine learning algorithms to analyze how drugs interact with functional brain circuitry while treating neurological diseases. Our trade secret approach has successfully classified drugs with useful action on epilepsy with 95% accuracy. This approach examines the transcriptomic and electrophysiological profile of how new drugs alter brain organoid function, giving us unique new insights into how effective the therapeutic approach can be in treating various pathologies. This allows pharmaceutical companies to not only identify ineffective drug candidates, but also to identify which patient populations would best be served by effective drug candidates before making the billion-dollar investment into human clinical trials.